Synthaverse S.A. (SVE.WA)
PLN 4.28
(7.0%)
PLN 4.28
(7.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 35.16 Million PLN | 25.9% |
| 2022 | 27.93 Million PLN | 23.23% |
| 2021 | 22.66 Million PLN | 10.21% |
| 2020 | 20.56 Million PLN | -3.23% |
| 2019 | 21.25 Million PLN | 31.56% |
| 2018 | 16.15 Million PLN | 15.06% |
| 2017 | 14.04 Million PLN | 5.52% |
| 2016 | 13.3 Million PLN | 68.94% |
| 2015 | 7.87 Million PLN | -50.16% |
| 2014 | 15.8 Million PLN | -41.46% |
| 2013 | 26.99 Million PLN | 14.72% |
| 2012 | 23.53 Million PLN | -19.62% |
| 2011 | 29.28 Million PLN | 22.48% |
| 2010 | 23.9 Million PLN | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 7.4 Million PLN | -42.4% |
| 2024 Q2 | 9.43 Million PLN | 27.35% |
| 2023 Q4 | 12.85 Million PLN | 151.27% |
| 2023 Q3 | 5.11 Million PLN | -54.18% |
| 2023 Q2 | 11.16 Million PLN | 85.17% |
| 2023 FY | 35.16 Million PLN | 25.9% |
| 2023 Q1 | 6.03 Million PLN | -27.97% |
| 2022 Q4 | 8.37 Million PLN | 13.73% |
| 2022 Q3 | 7.36 Million PLN | -16.32% |
| 2022 Q2 | 8.79 Million PLN | 158.58% |
| 2022 Q1 | 3.4 Million PLN | -59.34% |
| 2022 FY | 27.93 Million PLN | 23.23% |
| 2021 Q1 | 3.21 Million PLN | -54.84% |
| 2021 Q2 | 8.01 Million PLN | 149.38% |
| 2021 Q3 | 3.07 Million PLN | -61.57% |
| 2021 FY | 22.66 Million PLN | 10.21% |
| 2021 Q4 | 8.36 Million PLN | 171.8% |
| 2020 Q4 | 7.11 Million PLN | 104.34% |
| 2020 FY | 20.56 Million PLN | -3.23% |
| 2020 Q1 | 5.82 Million PLN | -10.85% |
| 2020 Q2 | 4.15 Million PLN | -28.73% |
| 2020 Q3 | 3.48 Million PLN | -16.12% |
| 2019 FY | 21.25 Million PLN | 31.56% |
| 2019 Q1 | 5.33 Million PLN | 19.0% |
| 2019 Q2 | 4.87 Million PLN | -8.52% |
| 2019 Q3 | 4.51 Million PLN | -7.48% |
| 2019 Q4 | 6.53 Million PLN | 44.77% |
| 2018 Q4 | 4.48 Million PLN | 16.03% |
| 2018 Q3 | 3.86 Million PLN | -9.24% |
| 2018 Q2 | 4.25 Million PLN | 19.53% |
| 2018 Q1 | 3.55 Million PLN | -3.26% |
| 2018 FY | 16.15 Million PLN | 15.06% |
| 2017 Q3 | 4.94 Million PLN | 232.3% |
| 2017 FY | 14.04 Million PLN | 5.52% |
| 2017 Q4 | 3.67 Million PLN | -25.65% |
| 2017 Q2 | 1.48 Million PLN | -52.75% |
| 2017 Q1 | 3.15 Million PLN | 23.71% |
| 2016 Q3 | 2.61 Million PLN | -39.49% |
| 2016 Q4 | 2.54 Million PLN | -2.67% |
| 2016 FY | 13.3 Million PLN | 68.94% |
| 2016 Q1 | 3.81 Million PLN | 651.17% |
| 2016 Q2 | 4.32 Million PLN | 13.28% |
| 2015 Q2 | 4.46 Million PLN | 227.7% |
| 2015 Q3 | 1.54 Million PLN | -65.31% |
| 2015 FY | 7.87 Million PLN | -50.16% |
| 2015 Q4 | 508.27 Thousand PLN | -67.14% |
| 2015 Q1 | 1.36 Million PLN | 167.11% |
| 2014 Q3 | 5.23 Million PLN | -24.29% |
| 2014 FY | 15.8 Million PLN | -41.46% |
| 2014 Q1 | 5.69 Million PLN | -23.17% |
| 2014 Q2 | 6.9 Million PLN | 21.35% |
| 2014 Q4 | -2.02 Million PLN | -138.77% |
| 2013 Q4 | 7.4 Million PLN | 13.3% |
| 2013 Q2 | 5.94 Million PLN | -16.33% |
| 2013 Q3 | 6.54 Million PLN | 10.02% |
| 2013 Q1 | 7.1 Million PLN | 126.71% |
| 2013 FY | 26.99 Million PLN | 14.72% |
| 2012 Q4 | 3.13 Million PLN | -9.81% |
| 2012 FY | 23.53 Million PLN | -19.62% |
| 2012 Q2 | 6.89 Million PLN | -31.29% |
| 2012 Q3 | 3.47 Million PLN | -49.6% |
| 2012 Q1 | 10.03 Million PLN | 0.0% |
| 2011 FY | 29.28 Million PLN | 22.48% |
| 2010 FY | 23.9 Million PLN | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioceltix S.A. | -1.03 Million PLN | 3487.71% |
| BIOTON S.A. | 72.85 Million PLN | 51.729% |
| Captor Therapeutics Spolka Akcyjna | 6.9 Million PLN | -409.593% |
| Mabion S.A. | 114.58 Million PLN | 69.309% |
| Molecure S.A. | -4.1 Million PLN | 957.395% |
| NanoGroup S.A. | -79.01 Thousand PLN | 44605.613% |
| Pharmena S.A. | 5.84 Million PLN | -501.865% |
| Poltreg S.A. | -1.38 Million PLN | 2635.472% |
| Pure Biologics Spólka Akcyjna | -2.57 Million PLN | 1466.239% |
| Ryvu Therapeutics S.A. | 29.3 Million PLN | -19.999% |
| Urteste S.A. | -479 Thousand PLN | 7441.754% |